{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T16:31:46Z","timestamp":1786465906469,"version":"build-2736575974"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,11]]},"DOI":"10.7759\/cureus.114350","type":"journal-article","created":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T15:20:55Z","timestamp":1786461655000},"source":"Crossref","is-referenced-by-count":0,"title":["Neuropsychiatric Effects of Glucagon-Like Peptide-1 Receptor Agonists in Schizophrenia-Spectrum Disorders: A Systematic Review"],"prefix":"10.7759","author":[{"given":"Zakariya Y","family":"Alsanosi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah S","family":"Alshahrani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulaziz A","family":"Nammazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar A","family":"Alsunusi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulrahman A","family":"Moafa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibtihal H","family":"Hadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed A","family":"Alabdali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah W","family":"Alhaqbani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Razan A","family":"Shahat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahd A","family":"Albeladi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aljoudi A","family":"Almajdoa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2025.2332","article-title":"Semaglutide treatment of antipsychotic-treated patients with schizophrenia, prediabetes, and obesity. The HISTORI randomized clinical trial","volume":"82","author":"Ganeshalingam AA","year":"2025","unstructured":"Ganeshalingam AA, Uhrenholt N, Arnfred S, et al.. Semaglutide treatment of antipsychotic-treated patients with schizophrenia, prediabetes, and obesity. The HISTORI randomized clinical trial. JAMA Psychiatry. 2025, 82:1065-74. 10.1001\/jamapsychiatry.2025.2332","journal-title":"JAMA Psychiatry"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(25)00129-4","article-title":"Efficacy and safety of semaglutide versus placebo for people with schizophrenia on clozapine with obesity (COaST): a phase 2, multi-centre, participant and investigator- blinded, randomised controlled trial in Australia","volume":"12","author":"Siskind D","year":"2025","unstructured":"Siskind D, Baker A, Arnautovska U, et al.. Efficacy and safety of semaglutide versus placebo for people with schizophrenia on clozapine with obesity (COaST): a phase 2, multi-centre, participant and investigator- blinded, randomised controlled trial in Australia. Lancet Psychiatry. 2025, 12:493-503. 10.1016\/S2215-0366(25)00129-4","journal-title":"Lancet Psychiatry"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1111\/acps.12711","article-title":"No cognitive-enhancing effect of GLP-1 receptor agonism in antipsychotic-treated, obese patients with schizophrenia","volume":"136","author":"Ish\u00f8y PL","year":"2017","unstructured":"Ish\u00f8y PL, Fagerlund B, Broberg BV, Bak N, Knop FK, Glenth\u00f8j BY, Ebdrup BH. No cognitive-enhancing effect of GLP-1 receptor agonism in antipsychotic-treated, obese patients with schizophrenia. Acta Psychiatr Scand. 2017, 136:52-62. 10.1111\/acps.12711","journal-title":"Acta Psychiatr Scand"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12795","article-title":"Effect of GLP-1 receptor agonist treatment on body weight in obese antipsychotic-treated patients with schizophrenia: a randomized, placebo-controlled trial","volume":"19","author":"Ish\u00f8y PL","year":"2017","unstructured":"Ish\u00f8y PL, Knop FK, Broberg BV, et al.. Effect of GLP-1 receptor agonist treatment on body weight in obese antipsychotic-treated patients with schizophrenia: a randomized, placebo-controlled trial. Diabetes Obes Metab. 2017, 19:162-71. 10.1111\/dom.12795","journal-title":"Diabetes Obes Metab"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2017.1220","article-title":"Effect of liraglutide treatment on prediabetes and overweight or obesity in clozapine- or olanzapine-treated patients with schizophrenia spectrum disorder: a randomized clinical trial","volume":"74","author":"Larsen JR","year":"2017","unstructured":"Larsen JR, Vedtofte L, Jakobsen MS, et al.. Effect of liraglutide treatment on prediabetes and overweight or obesity in clozapine- or olanzapine-treated patients with schizophrenia spectrum disorder: a randomized clinical trial. JAMA Psychiatry. 2017, 74:719-28. 10.1001\/jamapsychiatry.2017.1220","journal-title":"JAMA Psychiatry"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1111\/acps.12982","article-title":"One-year follow-up on liraglutide treatment for prediabetes and overweight\/obesity in clozapine- or olanzapine-treated patients","volume":"139","author":"Svensson CK","year":"2019","unstructured":"Svensson CK, Larsen JR, Vedtofte L, et al.. One-year follow-up on liraglutide treatment for prediabetes and overweight\/obesity in clozapine- or olanzapine-treated patients. Acta Psychiatr Scand. 2019, 139:26-36. 10.1111\/acps.12982","journal-title":"Acta Psychiatr Scand"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.rec.2021.07.010","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"74","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Rev Esp Cardiol (Engl Ed). 2021, 74:790-9. 10.1016\/j.rec.2021.07.010","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1186\/1472-6947-7-16","article-title":"Utilization of the PICO framework to improve searching PubMed for clinical questions","volume":"7","author":"Schardt C","year":"2007","unstructured":"Schardt C, Adams MB, Owens T, Keitz S, Fontelo P. Utilization of the PICO framework to improve searching PubMed for clinical questions. BMC Med Inform Decis Mak. 2007, 7:16. 10.1186\/1472-6947-7-16","journal-title":"BMC Med Inform Decis Mak"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne JA","year":"2019","unstructured":"Sterne JA, Savovi\u0107 J, Page MJ, et al.. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019, 366:l4898. 10.1136\/bmj.l4898","journal-title":"BMJ"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2010.09.011","article-title":"GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology","volume":"64","author":"Guyatt GH","year":"2011","unstructured":"Guyatt GH, Oxman AD, Sch\u00fcnemann HJ, Tugwell P, Knottnerus A. GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology. J Clin Epidemiol. 2011, 64:380-2. 10.1016\/j.jclinepi.2010.09.011","journal-title":"J Clin Epidemiol"},{"key":"ref11","article-title":"Positive and Negative Syndrome Scale (PANSS) training: challenges, solutions, and future directions","volume":"14","author":"Opler MGA","year":"2017","unstructured":"Opler MGA, Yavorsky C, Daniel DG. Positive and Negative Syndrome Scale (PANSS) training: challenges, solutions, and future directions. Innov Clin Neurosci. 2017, 14:77-81.","journal-title":"Innov Clin Neurosci"},{"key":"ref12","article-title":"The clinical global impressions scale: applying a research tool in clinical practice","volume":"4","author":"Busner J","year":"2007","unstructured":"Busner J, Targum SD. The clinical global impressions scale: applying a research tool in clinical practice. Psychiatry (Edgmont). 2007, 4:28-37.","journal-title":"Psychiatry (Edgmont)"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2020.12.044","article-title":"Standardized training in the rating of the six-item Positive And Negative Syndrome Scale (PANSS-6)","volume":"228","author":"K\u00f8lb\u00e6k P","year":"2021","unstructured":"K\u00f8lb\u00e6k P, Dines D, Hansen J, Opler M, Correll CU, Mors O, \u00d8stergaard SD. Standardized training in the rating of the six-item Positive And Negative Syndrome Scale (PANSS-6). Schizophr Res. 2021, 228:438-46. 10.1016\/j.schres.2020.12.044","journal-title":"Schizophr Res"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2003.09.011","article-title":"The Brief Assessment of Cognition in Schizophrenia: reliability, sensitivity, and comparison with a standard neurocognitive battery","volume":"68","author":"Keefe RS","year":"2004","unstructured":"Keefe RS, Goldberg TE, Harvey PD, Gold JM, Poe MP, Coughenour L. The Brief Assessment of Cognition in Schizophrenia: reliability, sensitivity, and comparison with a standard neurocognitive battery. Schizophr Res. 2004, 68:283-97. 10.1016\/j.schres.2003.09.011","journal-title":"Schizophr Res"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.306.6890.1437","article-title":"Short form 36 (SF36) health survey questionnaire: normative data for adults of working age","volume":"306","author":"Jenkinson C","year":"1993","unstructured":"Jenkinson C, Coulter A, Wright L. Short form 36 (SF36) health survey questionnaire: normative data for adults of working age. BMJ. 1993, 306:1437-40. 10.1136\/bmj.306.6890.1437","journal-title":"BMJ"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2008.04.037","article-title":"Validation of the Personal and Social Performance (PSP) Scale in a German sample of acutely ill patients with schizophrenia","volume":"104","author":"Juckel G","year":"2008","unstructured":"Juckel G, Schaub D, Fuchs N, et al.. Validation of the Personal and Social Performance (PSP) Scale in a German sample of acutely ill patients with schizophrenia. Schizophr Res. 2008, 104:287-93. 10.1016\/j.schres.2008.04.037","journal-title":"Schizophr Res"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.177.1.42","article-title":"Self-report quality of life measure for people with schizophrenia: the SQLS","volume":"177","author":"Wilkinson G","year":"2000","unstructured":"Wilkinson G, Hesdon B, Wild D, et al.. Self-report quality of life measure for people with schizophrenia: the SQLS. Br J Psychiatry. 2000, 177:42-6. 10.1192\/bjp.177.1.42","journal-title":"Br J Psychiatry"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/525111-neuropsychiatric-effects-of-glucagon-like-peptide-1-receptor-agonists-in-schizophrenia-spectrum-disorders-a-systematic-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T15:20:56Z","timestamp":1786461656000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/525111-neuropsychiatric-effects-of-glucagon-like-peptide-1-receptor-agonists-in-schizophrenia-spectrum-disorders-a-systematic-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,11]]},"references-count":17,"URL":"https:\/\/doi.org\/10.7759\/cureus.114350","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8,11]]}}}